Matrix Metalloproteinase Inhibition Attenuates Atrial Remodeling and Vulnerability to Atrial Fibrillation in a Canine Model of Heart Failure

Journal of Cardiac Failure

Volumn 14, Issue 9, 2008, Pages 768-776

  Moe, Gordon W ^a   Laurent, Gabriel ^a   Doumanovskaia, Liia ^a   Konig, Andrea ^a   Hu, Xudong ^a   Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Atrial fibrillation; matrix metalloproteinases; structural remodeling

Indexed keywords

CARDIOVASCULAR AGENT; COLLAGEN; GELATINASE; GELATINASE B; PGE 7113313; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOG; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART PACING; HEART SIZE; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DOGS; HEART FAILURE; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS;

EID: 55149121805     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.07.229     Document Type: Article

References (50)

1. Cohn J.N. New therapeutic strategies for heart failure: left ventricular remodeling as a target. J Card Fail 10 (2004) S200-S201
2. Fedak P.W., Verma S., Weisel R.D., et al. Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol 14 (2005) 1-11
3. Mann D.L. Basic mechanisms of left ventricular remodeling: the contribution of wall stress. J Card Fail 10 (2004) S202-S206
4. Boixel C., Fontaine V., Rucker-Martin C., et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 42 (2003) 336-344
5. Moe G.W., Grima E.A., Howard R.J., et al. Biatrial appendage hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure. J Card Fail 2 (1996) 127-132
6. Nakai T., Lee R.J., Schiller N.B., et al. The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery. Am Heart J 143 (2002) 181-186
7. Rossi A., Cicoira M., Zanolla L., et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol 40 (2002) 1425
8. Khan A., Moe G.W., Nili N., et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 43 (2004) 68-76
9. O'Brien D.W., Fu Y., Parker H.R., et al. Differential morphometric and ultrastructural remodelling in the left atrium and left ventricle in rapid ventricular pacing-induced heart failure. Can J Cardiol 16 (2000) 1411-1419
10. Knight B.P. Atrial fibrillation in patients with congestive heart failure. Pacing Clin Electrophysiol 26 (2003) 1620-1623
11. Maisel W.H., and Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91 (2003) 2D-8D
12. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107 (2003) 2920-2925
13. Spach M.S., and Dolber P.C. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle. Evidence for electrical uncoupling of side-to-side fiber connections with increasing age. Circ Res 58 (1986) 356-371
14. Nattel S., Shiroshita-Takeshita A., Brundel B.J., et al. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 48 (2005) 9-28
15. Fareh S., Villemaire C., and Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 98 (1998) 2202-2209
16. Gaspo R., Bosch R.F., Talajic M., et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 96 (1997) 4027-4035
17. Li D., Fareh S., Leung T.K., et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100 (1999) 87-95
18. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001) 2608-2614
19. Benjamin I.J. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Investig Med 49 (2001) 381-397
20. Vu T.H., and Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14 (2000) 2123-2133
21. Verma R.P., and Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 15 (2007) 2223-2268
22. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
23. Shastry S., Hayden M.R., Lucchesi P.A., et al. Matrix metalloproteinase in left ventricular remodeling and heart failure. Curr Cardiol Rep 5 (2003) 200-204
24. Sierevogel M.J., Pasterkamp G., De Kleijn D.P., et al. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 9 (2003) 1033-1040
25. Spinale F.G., Coker M.L., Krombach S.R., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85 (1999) 364-376
26. Apple K.A., Yarbrough W.M., Mukherjee R., et al. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol 47 (2006) 228-235
27. Laurent G., Moe G., Hu X., et al. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc Res 77 (2008) 89-97
28. Laurent G., Moe G.W., Hu X., et al. Experimental studies of atrial fibrillation: comparison of two pacing models. Am J Physiol Heart Circ Physiol 294 (2008) H1206-H1215 Epub 2008 Jan 4
29. Laurent G., Moe G.W., Hu X., et al. Simultaneous right atrioventricular pacing: a novel model to study atrial remodeling and atrial fibrillation in the setting of heart failure. J Card Fail 14 (2008) 254-262
30. Pikul S., Dow Dunham K.L., Almstead N.G., et al. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. J Med Chem 42 (1999) 87-94
31. King M.K., Coker M.L., Goldberg A., et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res 92 (2003) 177-185
32. Louie E.K., Liu D., Reynertson S.I., et al. "Stunning" of the left atrium after spontaneous conversion of atrial fibrillation to sinus rhythm: demonstration by transesophageal Doppler techniques in a canine model. J Am Coll Cardiol 32 (1998) 2081-2086
33. Howard R.J., Moe G.W., and Armstrong P.W. Sequential echocardiographic-Doppler assessment of left ventricular remodelling and mitral regurgitation during evolving experimental heart failure. Cardiovasc Res 25 (1991) 468-474
34. Moe G.W., Angus C., Howard R.J., et al. Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure. Cardiovasc Res 24 (1990) 570-577
35. Courtman D.W., Franco C.D., Meng Q., et al. Inward remodeling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline. J Vasc Res 41 (2004) 157-165
36. Koura T., Hara M., Takeuchi S., et al. Anisotropic conduction properties in canine atria analyzed by high-resolution optical mapping: preferential direction of conduction block changes from longitudinal to transverse with increasing age. Circulation 105 (2002) 2092-2098
37. Maquart F.X., Bellon G., Chaqour B., et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest 92 (1993) 2368-2376
38. Xu J., Cui G., Esmailian F., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 (2004) 363-368
39. Shinagawa K., Li D., Leung T.K., et al. Consequences of atrial tachycardia-induced remodeling depend on the preexisting atrial substrate. Circulation 105 (2002) 251-257
40. Li D., Melnyk P., Feng J., et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101 (2000) 2631-2638
41. Corbel M., Caulet-Maugendre S., Germain N., et al. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. J Pathol 193 (2001) 538-545
42. Falk V., Soccal P.M., Grunenfelder J., et al. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury. Eur J Cardiothorac Surg 22 (2002) 53-58
43. Li Y.Y., Kadokami T., Wang P., et al. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 282 (2002) H983-H989
44. Li Y.Y., Feng Y.Q., Kadokami T., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 97 (2000) 12746-12751
45. Siwik D.A., Chang D.L., and Colucci W.S. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86 (2000) 1259-1265
46. Moe G.W., Marin-Garcia J., Konig A., et al. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 287 (2004) H1813-H1820
47. Bradham W.S., Moe G., Wendt K.A., et al. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol 282 (2002) H1288-H1295
48. Cleland J.G., Coletta A.P., Freemantle N., et al. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER 5. Eur J Heart Fail 7 (2005) 931-936
49. Peterson J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 69 (2006) 677-687
50. Spinale F.G., Coker M.L., Thomas C.V., et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495